MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.95 -0.12 (-0.34%)
Official Closing Price Updated: 7:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
33 34 Next >
News headline image
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
News headline image
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
News headline image
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report ↗
The company also raised its outlook for the year. 
Via Investor's Business Daily
News headline image
My Top 10 Portfolio Holdings for 2025 ↗
This combination of growth and value stocks has the potential to outperform the broader market in 2025 (and beyond). 
Via The Motley Fool
News headline image
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
News headline image
Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
The S&P 500 and Dow Jones Industrial Average dropped by 0.4% and 0.6% respectively, while the Nasdaq 100 declined by 0.3%. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug ↗
Teva and Sanofi are partnered on a drug to treat inflammatory bowel disease. The drug showed "best-in-class potential" in midstage testing. 
Via Investor's Business Daily
News headline image
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? ↗
Teva and Sanofi's Phase 2b RELIEVE UCCD study shows duvakitug improves remission in ulcerative colitis and response in Crohn's disease. 
Via Benzinga
News headline image
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call today at 8:00 a.m. ET (U.S.) 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? ↗
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Is SoundHound AI a Millionaire-Maker Stock? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
News headline image
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids ↗
 
Via Benzinga
News headline image
Teva to Present at the Jefferies London Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript ↗
TEVA earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast ↗
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion. 
Via Benzinga
News headline image
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Statement on European Commission Decision; Company to Appeal
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story